CL2013002871A1 - Compuestos derivados de 1,3-oxazinas con actividad inhibidora de bace 1 y bace 2; composición farmacéutica que los comprende; procedimiento de preparación; uso en el tratamiento de la enfermedad de alzheimer, diabetes tipo 2, trombosis arterial, cáncer, infarto al miocardio,lupus eritematoso, entre otros. - Google Patents
Compuestos derivados de 1,3-oxazinas con actividad inhibidora de bace 1 y bace 2; composición farmacéutica que los comprende; procedimiento de preparación; uso en el tratamiento de la enfermedad de alzheimer, diabetes tipo 2, trombosis arterial, cáncer, infarto al miocardio,lupus eritematoso, entre otros.Info
- Publication number
- CL2013002871A1 CL2013002871A1 CL2013002871A CL2013002871A CL2013002871A1 CL 2013002871 A1 CL2013002871 A1 CL 2013002871A1 CL 2013002871 A CL2013002871 A CL 2013002871A CL 2013002871 A CL2013002871 A CL 2013002871A CL 2013002871 A1 CL2013002871 A1 CL 2013002871A1
- Authority
- CL
- Chile
- Prior art keywords
- bace
- oxazines
- alzheimer
- diabetes
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
- C07D265/08—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D265/10—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/28—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
- C07D265/08—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11161803 | 2011-04-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2013002871A1 true CL2013002871A1 (es) | 2014-05-09 |
Family
ID=45932341
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2013002871A CL2013002871A1 (es) | 2011-04-11 | 2013-10-07 | Compuestos derivados de 1,3-oxazinas con actividad inhibidora de bace 1 y bace 2; composición farmacéutica que los comprende; procedimiento de preparación; uso en el tratamiento de la enfermedad de alzheimer, diabetes tipo 2, trombosis arterial, cáncer, infarto al miocardio,lupus eritematoso, entre otros. |
Country Status (19)
Country | Link |
---|---|
US (3) | US8754075B2 (es) |
EP (1) | EP2697208A1 (es) |
JP (1) | JP5721157B2 (es) |
KR (1) | KR20140002039A (es) |
CN (1) | CN103502227A (es) |
AR (1) | AR085960A1 (es) |
AU (1) | AU2012241955A1 (es) |
CA (1) | CA2832467A1 (es) |
CL (1) | CL2013002871A1 (es) |
CO (1) | CO7071122A2 (es) |
CR (1) | CR20130432A (es) |
EA (1) | EA201391468A1 (es) |
EC (1) | ECSP13012967A (es) |
IL (1) | IL228104A0 (es) |
MA (1) | MA35114B1 (es) |
MX (1) | MX2013010795A (es) |
PE (1) | PE20141004A1 (es) |
SG (1) | SG193929A1 (es) |
WO (1) | WO2012139993A1 (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2628074C (en) | 2005-10-25 | 2014-01-14 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivative |
KR20100017255A (ko) | 2007-04-24 | 2010-02-16 | 시오노기 앤드 컴파니, 리미티드 | 환식기로 치환된 아미노다이하이드로싸이아진 유도체 |
WO2008133273A1 (ja) * | 2007-04-24 | 2008-11-06 | Shionogi & Co., Ltd. | アルツハイマー症治療用医薬組成物 |
US8637504B2 (en) | 2008-06-13 | 2014-01-28 | Shionogi & Co., Ltd. | Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity |
US8703785B2 (en) * | 2008-10-22 | 2014-04-22 | Shionogi & Co., Ltd. | 2-aminopyrimidin-4-one and 2-aminopyridine derivatives both having BACE1-inhibiting activity |
US8569310B2 (en) | 2009-10-08 | 2013-10-29 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions and their use |
EP2485591B1 (en) | 2009-10-08 | 2016-03-23 | Merck Sharp & Dohme Corp. | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
US8557826B2 (en) | 2009-10-08 | 2013-10-15 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions, and their use |
US8999980B2 (en) | 2009-12-11 | 2015-04-07 | Shionogi & Co., Ltd. | Oxazine derivatives |
EP2634186A4 (en) | 2010-10-29 | 2014-03-26 | Shionogi & Co | naphthyridine |
JP5766198B2 (ja) | 2010-10-29 | 2015-08-19 | 塩野義製薬株式会社 | 縮合アミノジヒドロピリミジン誘導体 |
WO2012138590A1 (en) | 2011-04-07 | 2012-10-11 | Merck Sharp & Dohme Corp. | Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
US9221839B2 (en) | 2011-04-07 | 2015-12-29 | Merck Sharp & Dohme Corp. | C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use |
US8754075B2 (en) * | 2011-04-11 | 2014-06-17 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE1 and/or BACE2 inhibitors |
EP2703399A4 (en) | 2011-04-26 | 2014-10-15 | Shionogi & Co | OXAZINE DERIVATIVE AND BACE-1 HEMMER THEREOF |
US8785436B2 (en) * | 2011-05-16 | 2014-07-22 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE 1 and/or BACE2 inhibitors |
JP5952898B2 (ja) * | 2011-06-07 | 2016-07-13 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | [1,3]オキサジン |
AU2012298983A1 (en) | 2011-08-22 | 2014-02-27 | Merck Sharp & Dohme Corp. | 2-spiro-substituted iminothiazines and their mono-and dioxides as BACE inhibitors, compositions and their use |
UY34278A (es) | 2011-08-25 | 2013-04-05 | Novartis Ag | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades |
US9067926B2 (en) * | 2012-01-26 | 2015-06-30 | Hoffmann-La Roche Inc. | Fluoromethyl-5,6-dihydro-4H-[1,3]OXAZINES |
WO2014065434A1 (en) | 2012-10-24 | 2014-05-01 | Shionogi & Co., Ltd. | Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity |
EP2961749B1 (en) * | 2013-03-01 | 2019-10-09 | Amgen Inc. | Perfluorinated 5,6-dihydro-4h-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
BR112015021336A2 (pt) | 2013-03-08 | 2017-07-18 | Amgen Inc | compostos 1,3-oxazin-2-amina fundidos ciclopropil perfluorados como inibidores de beta-secretase e métodos de uso |
BR112015019412A8 (pt) | 2013-04-11 | 2019-11-12 | Hoffmann La Roche | inibidores de bace1, seus usos, e composição farmacêutica |
JO3318B1 (ar) | 2013-06-18 | 2019-03-13 | Lilly Co Eli | مثبطات bace |
TW201609700A (zh) * | 2014-02-19 | 2016-03-16 | H 朗德貝克公司 | 2-胺基-3,5,5-三氟-3,4,5,6-四氫吡啶作爲bace1抑制劑用於治療阿茲海默症 |
TW201623295A (zh) | 2014-04-11 | 2016-07-01 | 塩野義製藥股份有限公司 | 具有bace1抑制活性之二氫噻及二氫衍生物 |
EP3177618A1 (en) | 2014-08-08 | 2017-06-14 | Amgen Inc. | Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use |
CN105566179B (zh) * | 2014-10-14 | 2017-09-05 | 上海工程技术大学 | 一种制备手性α‑氟‑β‑氨基酸衍生物的方法 |
JO3458B1 (ar) | 2014-11-10 | 2020-07-05 | H Lundbeck As | 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1 |
MA40941A (fr) | 2014-11-10 | 2017-09-19 | H Lundbeck As | 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 |
CR20170187A (es) * | 2014-11-10 | 2018-02-01 | H Lundbeck As | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer |
CA2979113A1 (en) | 2015-03-20 | 2016-09-29 | F. Hoffmann-La Roche Ag | Bace1 inhibitors |
TW201717948A (zh) | 2015-08-10 | 2017-06-01 | H 朗德貝克公司 | 包括給予2-胺基-3,5,5-三氟-3,4,5,6-四氫吡啶的聯合治療 |
US10011596B2 (en) | 2015-08-12 | 2018-07-03 | H. Lundbeck A/S | 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors |
CN107304176A (zh) * | 2016-04-21 | 2017-10-31 | 上海工程技术大学 | α-芳基取代的α-氟代β-氨基酸类化合物及其制备方法 |
CN112313238A (zh) | 2018-04-27 | 2021-02-02 | 盐野义制药株式会社 | 具有选择性bace1抑制活性的四氢吡喃并噁嗪衍生物 |
US12042492B2 (en) | 2020-10-09 | 2024-07-23 | Texas Tech University System | BACE1 inhibitory ligand molecules against amyloid beta-induced synaptic and mitochondrial toxicities |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9216298D0 (en) | 1991-08-15 | 1992-09-16 | Ici Plc | Piperidine derivatives |
AU7688398A (en) | 1997-06-16 | 1999-01-04 | American Home Products Corporation | Elevation of hdl cholesterol by 2-{(aminothioxomethyl)-hydrazono}-2-arylethyl carbamates |
CA2628074C (en) * | 2005-10-25 | 2014-01-14 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivative |
KR20100017255A (ko) | 2007-04-24 | 2010-02-16 | 시오노기 앤드 컴파니, 리미티드 | 환식기로 치환된 아미노다이하이드로싸이아진 유도체 |
US20090209757A1 (en) | 2008-01-10 | 2009-08-20 | Santiago Ini | Processes for the preparation and purification of paliperidone palmitate |
CA2711655C (en) | 2008-01-18 | 2013-03-05 | Eisai R&D Management Co., Ltd. | Condensed aminodihydrothiazine derivative |
TW201040141A (en) | 2009-03-31 | 2010-11-16 | Shionogi & Co | Isothiourea derivatives or isourea derivatives having BACE1 inhibitory activity |
GB0912778D0 (en) | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydro-oxazine derivatives |
UY32799A (es) | 2009-07-24 | 2011-02-28 | Novartis Ag | Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos |
US8188079B2 (en) | 2009-08-19 | 2012-05-29 | Hoffman-La Roche Inc. | 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines |
US7964594B1 (en) | 2009-12-10 | 2011-06-21 | Hoffmann-La Roche Inc. | Amino oxazine derivatives |
US8999980B2 (en) | 2009-12-11 | 2015-04-07 | Shionogi & Co., Ltd. | Oxazine derivatives |
UA103272C2 (uk) * | 2009-12-11 | 2013-09-25 | Ф. Хоффманн-Ля Рош Аг | 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2 |
US8754075B2 (en) * | 2011-04-11 | 2014-06-17 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE1 and/or BACE2 inhibitors |
-
2012
- 2012-04-05 US US13/439,893 patent/US8754075B2/en not_active Expired - Fee Related
- 2012-04-10 KR KR1020137029827A patent/KR20140002039A/ko active IP Right Grant
- 2012-04-10 AU AU2012241955A patent/AU2012241955A1/en not_active Abandoned
- 2012-04-10 PE PE2013002203A patent/PE20141004A1/es not_active Application Discontinuation
- 2012-04-10 JP JP2014504274A patent/JP5721157B2/ja not_active Expired - Fee Related
- 2012-04-10 SG SG2013071139A patent/SG193929A1/en unknown
- 2012-04-10 CA CA2832467A patent/CA2832467A1/en not_active Abandoned
- 2012-04-10 AR ARP120101219A patent/AR085960A1/es unknown
- 2012-04-10 EA EA201391468A patent/EA201391468A1/ru unknown
- 2012-04-10 EP EP12712669.6A patent/EP2697208A1/en not_active Withdrawn
- 2012-04-10 WO PCT/EP2012/056408 patent/WO2012139993A1/en active Application Filing
- 2012-04-10 MX MX2013010795A patent/MX2013010795A/es not_active Application Discontinuation
- 2012-04-10 CN CN201280017754.7A patent/CN103502227A/zh active Pending
-
2013
- 2013-08-22 IL IL228104A patent/IL228104A0/en unknown
- 2013-08-30 CO CO13206284A patent/CO7071122A2/es not_active Application Discontinuation
- 2013-08-30 CR CR20130432A patent/CR20130432A/es unknown
- 2013-10-07 CL CL2013002871A patent/CL2013002871A1/es unknown
- 2013-10-10 EC ECSP13012967 patent/ECSP13012967A/es unknown
- 2013-11-11 MA MA36414A patent/MA35114B1/fr unknown
-
2014
- 2014-05-02 US US14/268,085 patent/US9115098B2/en not_active Expired - Fee Related
-
2015
- 2015-07-20 US US14/803,746 patent/US20150322054A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
NZ614545A (en) | 2014-10-31 |
AU2012241955A1 (en) | 2013-09-12 |
EA201391468A1 (ru) | 2014-04-30 |
JP2014510769A (ja) | 2014-05-01 |
CR20130432A (es) | 2013-12-09 |
IL228104A0 (en) | 2013-09-30 |
CO7071122A2 (es) | 2014-09-30 |
US9115098B2 (en) | 2015-08-25 |
KR20140002039A (ko) | 2014-01-07 |
AR085960A1 (es) | 2013-11-06 |
CA2832467A1 (en) | 2012-10-18 |
EP2697208A1 (en) | 2014-02-19 |
WO2012139993A1 (en) | 2012-10-18 |
US20150322054A1 (en) | 2015-11-12 |
JP5721157B2 (ja) | 2015-05-20 |
US8754075B2 (en) | 2014-06-17 |
CN103502227A (zh) | 2014-01-08 |
ECSP13012967A (es) | 2013-11-29 |
MA35114B1 (fr) | 2014-05-02 |
SG193929A1 (en) | 2013-11-29 |
PE20141004A1 (es) | 2014-08-27 |
US20120258962A1 (en) | 2012-10-11 |
MX2013010795A (es) | 2013-12-06 |
US20140243325A1 (en) | 2014-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2013002871A1 (es) | Compuestos derivados de 1,3-oxazinas con actividad inhibidora de bace 1 y bace 2; composición farmacéutica que los comprende; procedimiento de preparación; uso en el tratamiento de la enfermedad de alzheimer, diabetes tipo 2, trombosis arterial, cáncer, infarto al miocardio,lupus eritematoso, entre otros. | |
CL2013003262A1 (es) | Compuestos derivados de 1,3-oxazinas, con actividad inhibidora de bace 1 y/o bace2; composición farmacéutica que los comprende; procedimiento de preparación; uso en el tratamiento de la enfermedad de alzheimer, diabetes, trombosis arterial, cáncer, infarto al miocardio, entre otras patologías. | |
CL2007002610A1 (es) | Compuestos derivados de bipiridina sustituida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o la profilaxis de enfermedades tales como hipertonia, diabetes, infarto de miocardio, entre otras. | |
CL2013003472A1 (es) | Compuestos derivados de halogenoalquil-1,3-oxazinas sustituidas, inhibidores de la bace1 y/o bace2; procedimiento de obtencion; composicion farmaceutica que los comprende; su uso en el tratamiento y/o profilaxis de enfermedades tales como diabetes, alzheimer, als, enfermedades autoinmunes inflamatorias, cancer, entre otras. | |
CL2013003598A1 (es) | Compuestos derivados de benzooxazepinona, moduladores de canales de sodio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades seleccionadas de arritmias, insuficiencia cardiaca, angina, infarto al miocardio, diabetes, entre otras | |
CL2008001994A1 (es) | Compuestos derivados de pirazin-2-ona; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, aterosclerosis, hipertension, entre otras. | |
CL2014001752A1 (es) | Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras. | |
CL2013003372A1 (es) | Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes. | |
CL2015001699A1 (es) | Compuestos derivados de nucleosidos, nucleotidos y analogos de los mismos; composicion farmaceutica; y su uso para preparar un medicamento util en el tratamiento de la hepatitis c. | |
CL2013002125A1 (es) | Compuestos derivados de imidazo[5,1-f][1,2,4]triazinas; composicion farmaceutica; y uso en el tratamiento del deterioro cognitivo asociado con esquizofrenia. | |
CL2008001921A1 (es) | Compuestos derivados de heterociclos sustituidos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como ictus, isquemia cerebral, alzheimer, dolor, entre otras. | |
CL2014001792A1 (es) | Compuestos derivados de carbamato; composicion farmaceutica, y uso de los mismos en el tratamiento del dolor, cancer por tumor solido, obesidad, entre otras enfermedades. | |
CL2014000458A1 (es) | Compuestos derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina; composicion y combinacion farmaceutica; y uso en el tratamiento o en la prevencion del alzheimer, diabetes tipo 2, obesidad, entre otras enfermedades. | |
CL2009000349A1 (es) | Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer. | |
CL2008000434A1 (es) | Compuestos derivados de 2-amino-oxazolinas; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, trastorno bipolar, entre otros. | |
CL2013001339A1 (es) | Compuestos derivados heterociclicos condensados, con actividad antiviral; composicion farmaceutica que los comprende; y su uso para la prevencion o tratamiento de la infeccion de vih. | |
CL2013001964A1 (es) | Compuestos derivados de heterociclos, como inhibidores de bace 1 o 2; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento o prevencion de la enfermedad de alzheimer o deterioro cognitivo leve, resistencia a la insulina, diabetes tipo 2, entre otras. | |
CL2012002896A1 (es) | Compuestos para tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide; composicion farmacéutica que lo comprende; uso del compuesto para retener o incrementar la memoria cognitiva. | |
CL2008001076A1 (es) | Compuestos derivados de sulfonamida; composicion farmaceutica; y uso en el tratamiento del cancer. | |
CL2008001215A1 (es) | Compuestos derivados de heterociclos nitrogenados condensados; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, dislipidemia, obesidad y alzheimer. | |
CL2014002557A1 (es) | Compuestos bicíclicos de pirazinona; procedimiento de preparacion; composicion farmaceutica; kit; y uso en el tratamiento y/o prevencion de enfermedades cardiovasculares, cancer, entre otras. | |
CL2012003427A1 (es) | Compuestos derivados de 5-amino-3,6-dihidro-1h-pirazina-2-ona; y uso en el tratamiento de enfermedades tales como alzheimer, senilidad, demencia, entre otras. | |
CL2014001060A1 (es) | Compuestos derivados de aril-quinolina; proceso de obtencion; composicion farmaceutica que los comprende y uso en el tratamiento o profilaxis de la diabetes tipo 2, la aterosclerosis, cancer, entre otras enfermedades. | |
CL2013001654A1 (es) | Compuestos derivados de 6-amino-2-fenilamino-1h-bencimidazol-5-carboxamida; composicion farmaceutica; y su uso en el tratamiento y/o prevencion de las enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor. | |
CL2007002593A1 (es) | Compuestos derivados de 4-heteroaril-piridina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como rechazo de organos transplantados, sindromes autoinmunes y cancer. |